Literature DB >> 16928680

ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis.

Charles W Joyce1, Elke M Wagner, Federica Basso, Marcelo J Amar, Lita A Freeman, Robert D Shamburek, Catherine L Knapper, Jafri Syed, Justina Wu, Boris L Vaisman, Jamila Fruchart-Najib, Eric M Billings, Beverly Paigen, Alan T Remaley, Silvia Santamarina-Fojo, H Bryan Brewer.   

Abstract

The identification of ABCA1 as a key transporter responsible for cellular lipid efflux has led to considerable interest in defining its role in cholesterol metabolism and atherosclerosis. In this study, the effect of overexpressing ABCA1 in the liver of LDLr-KO mice was investigated. Compared with LDLr-KO mice, ABCA1-Tg x LDLr-KO (ABCA1-Tg) mice had significantly increased plasma cholesterol levels, mostly because of a 2.8-fold increase in cholesterol associated with a large pool of apoB-lipoproteins. ApoB synthesis was unchanged but the catabolism of (125)I-apoB-VLDL and -LDL were significantly delayed, accounting for the 1.35-fold increase in plasma apoB levels in ABCA1-Tg mice. We also found rapid in vivo transfer of free cholesterol from HDL to apoB-lipoproteins in ABCA1-Tg mice, associated with a significant 2.7-fold increase in the LCAT-derived cholesteryl linoleate content found primarily in apoB-lipoproteins. ABCA1-Tg mice had 1.4-fold increased hepatic cholesterol concentrations, leading to a compensatory 71% decrease in de novo hepatic cholesterol synthesis, as well as enhanced biliary cholesterol, and bile acid secretion. CAV-1, CYP2b10, and ABCG1 were significantly induced in ABCA1-overexpressing livers; however, no differences were observed in the hepatic expression of CYP7alpha1, CYP27alpha1, or ABCG5/G8 between ABCA1-Tg and control mice. As expected from the pro-atherogenic plasma lipid profile, aortic atherosclerosis was increased 10-fold in ABCA1-Tg mice. In summary, hepatic overexpression of ABCA1 in LDLr-KO mice leads to: 1) expansion of the pro-atherogenic apoB-lipoprotein cholesterol pool size via enhanced transfer of HDL-cholesterol to apoB-lipoproteins and delayed catabolism of cholesterol-enriched apoB-lipoproteins; 2) increased cholesterol concentration in the liver, resulting in up-regulated hepatobiliary sterol secretion; and 3) significantly enhanced aortic atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928680     DOI: 10.1074/jbc.M604526200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Authors:  Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

2.  Selective evaluation of high density lipoprotein from mouse small intestine by an in situ perfusion technique.

Authors:  Satoshi Yamaguchi; Bo Zhang; Takeshi Tomonaga; Utako Seino; Akiko Kanagawa; Masaru Segawa; Hironori Nagasaka; Akira Suzuki; Takashi Miida; Sohsuke Yamada; Yasuyuki Sasaguri; Takefumi Doi; Keijiro Saku; Mitsuyo Okazaki; Yoshihiro Tochino; Ken-Ichi Hirano
Journal:  J Lipid Res       Date:  2014-02-25       Impact factor: 5.922

3.  Enhanced vascular permeability facilitates entry of plasma HDL and promotes macrophage-reverse cholesterol transport from skin in mice.

Authors:  Ilona Kareinen; Lídia Cedó; Reija Silvennoinen; Pirkka-Pekka Laurila; Matti Jauhiainen; Josep Julve; Francisco Blanco-Vaca; Joan Carles Escola-Gil; Petri T Kovanen; Miriam Lee-Rueckert
Journal:  J Lipid Res       Date:  2014-12-03       Impact factor: 5.922

Review 4.  Mechanisms of foam cell formation in atherosclerosis.

Authors:  Dimitry A Chistiakov; Alexandra A Melnichenko; Veronika A Myasoedova; Andrey V Grechko; Alexander N Orekhov
Journal:  J Mol Med (Berl)       Date:  2017-08-07       Impact factor: 4.599

5.  The thienotriazolodiazepine Ro 11-1464 increases plasma apoA-I and promotes reverse cholesterol transport in human apoA-I transgenic mice.

Authors:  I Zanotti; C Maugeais; M Pedrelli; M Gomaraschi; P Salgam; L Calabresi; F Bernini; H Kempen
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

6.  Exosome-Mediated Transfer of Anti-miR-33a-5p from Transduced Endothelial Cells Enhances Macrophage and Vascular Smooth Muscle Cell Cholesterol Efflux.

Authors:  Alexis Stamatikos; Ethan Knight; Lucia Vojtech; Lianxiang Bi; Bradley K Wacker; Chongren Tang; David A Dichek
Journal:  Hum Gene Ther       Date:  2020-01-16       Impact factor: 5.695

7.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.

Authors:  Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

8.  ABCA1 Overexpression in Endothelial Cells In Vitro Enhances ApoAI-Mediated Cholesterol Efflux and Decreases Inflammation.

Authors:  Alexis Stamatikos; Nagadhara Dronadula; Philip Ng; Donna Palmer; Ethan Knight; Bradley K Wacker; Chongren Tang; Francis Kim; David A Dichek
Journal:  Hum Gene Ther       Date:  2018-10-02       Impact factor: 5.695

9.  Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet.

Authors:  Federica Basso; Marcelo J Amar; Elke M Wagner; Boris Vaisman; Beverly Paigen; Silvia Santamarina-Fojo; Alan T Remaley
Journal:  Biochem Biophys Res Commun       Date:  2006-10-17       Impact factor: 3.575

10.  Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Tyler J Marquart; Judy Wu; Aldons J Lusis; Ángel Baldán
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-01-03       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.